neurological effects, such as headaches, a sense of restlessness, or trouble sleeping
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study
Less sustainable More people are becoming familiar with the term Ozempic Rebound, where people regain weight after they stop their semaglutide regimen
Anecdotally, many patients report a 30 to 50% reduction in peak nausea severity
Without semaglutide, participants relying solely on lifestyle changes shed approximately 2.4% of their weight in the same period
The SELECT trial took it further